Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 4, 2010, Pages 597-603

  Lemke, Andreas ^a   Kiderlen, Albrecht F ^b   Petri, Boris ^c   Kayser, Oliver ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ROBERT KOCH INSTITUTE   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Amphotericin B; Balamuthia mandrillaris; High pressure homogenization; In vitro in vivo correlation; Nanosuspension; Two dimensional polyacrylamide gel electrophoresis

Indexed keywords

AMPHOTERICIN B; BALAMUTHIA MANDRILLARIS; HIGH PRESSURE HOMOGENIZATION; IN-VITRO; NANO-SUSPENSIONS; TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS;

ADSORPTION; ELECTROPHORESIS; GELS; PHOTON CORRELATION SPECTROSCOPY; SODIUM; SURFACE ACTIVE AGENTS; TWO DIMENSIONAL;

BRAIN;

AMPHOTERICIN B; CHOLIC ACID; NANOPARTICLE; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BALAMUTHIA MANDRILLARIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; SUSPENSION;

AMEBIASIS; AMEBICIDES; AMOEBOZOA; AMPHOTERICIN B; ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; FEMALE; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; POLYSORBATES;

BALAMUTHIA MANDRILLARIS;

EID: 77955274105     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.12.004     Document Type: Article

References (20)

1. Lemke A., Kiderlen A.F., Kayser O. Amphotericin B. Appl Microbiol Biotechnol 2005, 68:151-162.
2. Dignani M.C., Anaissie E. Human fusariosis. Clin Microbiol Infect 2004, 10(Suppl):67-75.
3. Herbrecht R., Natarajan-Ame S., Nivoix Y. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003, 4:1277-1287.
4. Gallagher J.C., Dodds Ashley E.S., Drew R.H. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 2003, 4:147-164.
5. Kiderlen A.F., Laube U., Radam E. Oral infection of immunocompetent and immunodeficient mice with Balamuthia mandrillaris amoebae. Parasitol Res 2007, 100:775-782.
6. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19.
7. Göppert T.M., Müller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005, 13:179-187.
8. Visvesvara G.S., Schuster F.L., Martinez A.J. Balamuthia mandrillaris, N. G., N. Sp., agent of amebic meningoencephalitis in humans and other animals. J Eukaryot Microbiol. 1993, 40:504-514.
9. Schuster F.L., Visvesvara G.S. Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. J Clin Microbiol 1996, 34:385-388.
10. Kiderlen A.F., Tata P.S., Özel M. Cytopathogenicity of Balamuthia mandrillaris, an opportunistic causative agent of granulomatous amebic encephalitis. J Eukaryot Microbiol 2006, 53:456-463.
11. Schäfer H., Schäfer A., Kiderlen A.F., Masihi K.N., Burger R. A highly sensitive cytotoxicity assay based on the release of reporter enzymes from stably transfected cell lines. J Immunol Methods 1997, 204:89-98.
12. Kiderlen A.F. Laube U. Balamuthia mandrillaris, an opportunistic agent of granulomatous amebic encephalitis, infects the brain via the olfactory nerve pathway. Parasitol Res 2004, 94:49-52.
13. Buttle I., Schmidt S., Müller R.H. Production of amphotericin B emulsions based on SolEmuls technology. Proceedings of the 4th World Meeting Pharm, Biopharm and Pharm Technology, Florence, Italy 2002, 1535-1536. APV Mainz, Germany.
14. Collette N., van der Auwera P., Lopez A.P., et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989, 33:362-368.
15. Blunk T., Hochstrasser D.F., Sanchez J.C. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1993, 14:1382-1387.
16. Harnisch S., Müller R.H. Plasma protein adsorption patterns on emulsions for parenteral administration: establishment of a protocol for two-dimensional polyacrylamide electrophoresis. Electrophoresis 1998, 19:349-354.
17. Hochstrasser D.F., Harrington M.G., Hochstrasser A.C. Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 1988, 173:424-435.
18. Blunk T. Plasma protein adsorption onto colloidal drug carriers. PhD Thesis. Free University Berlin, Berlin, Germany, 1994.
19. Kane R.S., Stroock A.D. Nanobiotechnology: protein-nanomaterial interactions. Biotechnol Prog 2007, 23:316-319.
20. Gessner A., Olbrich C., Schröder W., Müller R.H. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 2001, 214:87-91.